A potent (R)-alpha-bis-lipoyl derivative containing 8-hydroxyquinoline scaffold: Synthesis and biological evaluation of its neuroprotective capabilities in SH-SY5Y human neuroblastoma cells

Pharmaceuticals

Volumn 6, Issue 1, 2013, Pages 54-69

  Cacciatore, Ivana ^a   Fornasari, Erika ^a   Baldassarre, Leonardo ^a   Cornacchia, Catia ^a   Fulle, Stefania ^a,b   Di Filippo, Ester Sara ^a,b   Pietrangelo, Tiziana ^a,b   Pinnen, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b CeSI Centro Studi Invecchiamento   (Italy)

Author keywords

(R) alpha lipoic acid; 8 hydroxyquinoline; Antioxidants; Neurodegenerative diseases; Neuroprotective agent

Indexed keywords

1 [5 [1,2] DITHIOLAN 3 YL PEMTANOYL]PYRROLIDINE 2,5 DIONE; 5 HYDROXYMETHYL 8 HYDROXYQUINOLINE; 8 QUINOLINOL; ALPHA BIS LIPOYL DERIVATIVE; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; TETRAZOLIUM; THIOCTIC ACID; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL STRUCTURE; CHELATION; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATIVE STRESS; PHENOTYPE;

EID: 84872164177     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6010054     Document Type: Article

References (39)

1. Mark, P.M. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann. N.Y. Acad. Sci. 2004, 1012, 37-50.
2. Jellinger, K.A. General aspects of neurodegeneration. J. Neural Transm. Suppl. 2003, 65, 101-144.
3. Lepoivre, M.; Flaman, J.M.; Bobè, P.; Lemaire, G.; Henry, Y. Quenching of the tyrosyl free radical of ribonucleotide reductase by nitric oxide. J. Bio. Chem. 1994, 269, 21891-21897.
4. Bush, A.I. Metals and neuroscience. Curr. Opin. Chem. Biol. 2000, 4, 184-191.
5. Cricthton, R.R.; Dexter, D.T.; Ward, R.J. Metal based neurodegenerative diseases - From molecular mechanism to therapeutic strategies. Coordin. Chem. Rev. 2008, 252, 1189-1199.
6. Schulz, J.B.; Lindenau, J.; Seyfried, J. Dichganz, J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 2000, 267, 4904-4911.
7. Cuajungco, M.P.; Faget, K.Y.; Huang, X.; Tanzi, R.E.; Bush, A.I. Metal chelation as a potential therapy for Alzheimer's disease. Ann. N.Y. Acad. Sci. 2000, 920, 292-304.
8. Sozio, P.; Iannitelli, A.; Cerasa, L.S.; Cacciatore, I; Cornacchia, C.; Giorgioni, G.; Ricciutelli, M.; Nasuti, C.; Cantalamessa, F.; Di Stefano, A. New L-Dopa codrugs as potential antiparkinson agents. Arch. Pharm. 2008, 341, 412-417.
9. Cacciatore, I.; Cornacchia, C.; Pinnen, F.; Mollica, A.; Di Stefano, A. Prodrug approach for increasing cellular glutathione levels. Molecules 2010, 15, 1242-1264.
10. Cornacchia, C.; Cacciatore, I.; Baldassarre, L.; Mollica, A.; Feliciani, F.; Pinnen, F. Diketopiperazines as neuroprotective agents. Mini-Rev. Med. Chem. 2012, 12, 2-12.
11. Pinnen, F.; Cacciatore, I.; Cornacchia, C.; Mollica, A.; Sozio, P.; Cerasa, L.S.; Iannitelli, A.; Fontana, A.; Nasuti, C.; Di Stefano, A. CNS delivery of L-dopa by a new hybrid glutathione- methionine peptidomimetic prodrug. Amino Acids 2012, 42, 261-269.
12. Minelli, A.; Conte, C.; Grottelli, S.; Bellezza, I.; Cacciatore, I.; Bolaños, J. Cyclo(His-Pro) promotes cytoprotection by activating Nrf2-mediated up-regulation of antioxidant defence. J. Cell. Mol. Med. 2009, 13, 1149-1161.
13. Minelli, A.; Conte, C.; Prudenzi, E.; Cacciatore, I.; Cornacchia, C.; Taha, E.; Pinnen, F. N-acetyl- L-methionyl-L-Dopa- methyl ester as a dual acting drug that relives L-Dopa-induced oxidative toxicity. Free Radical Bio. Med. 2010, 49, 31-39.
14. Minelli, A.; Conte, C.; Cacciatore, I.; Cornacchia, C.; Pinnen, F. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-Dopa in a Parkinson's animal model. Amino Acids 2012, 43, 1359-1367.
15. Cacciatore, I.; Cornacchia, C.; Baldassarre, L.; Fornasari, E.; Mollica, A.; Stefanucci, A.; Pinnen, F. GPE and GPE analogues as promising neuroprotective agents. Mini-Rev. Med. Chem. 2012, 12, 13-23.
16. Pinnen, F.; Sozio, P.; Cacciatore, I.; Cornacchia, C.; Mollica, A.; Iannitelli, A.; D'Aurizio, E.; Cataldi, A.; Zara, S.; Nasuti, C.; Di Stefano, A. Ibuprofen and glutathione conjugate as a potential therapeutic agent for treating Alzheimer's disease. Arch. Pharm. 2011, 344, 139-148.
17. Bongarzone, S.; Bolognesi, M.L. The concept of privileged structures in rational drug design: Focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. Expert Opin. Drug Dis. 2011, 6, 251-268.
18. Frederickson, C.J.; Kasarskis, E.J.; Ringo, D.; Frederickson, R.E. A quinoline fluorescence method for visualizing and assayingthe hystochemically and reactive zinc (bouton zinc) in the brain. J. Neurosci. Methods 1987, 20, 91-103.
19. Turnquist, T.D.; Sandell, E.B. Stability constants of iron (III)-8-hydroxyquinoline complexes. Anal. Chim. Acta 1968, 42, 239-245.
20. Kayyali, R.; Pannala, A.S.; Khodr, H.; Hider, R.C. Comparative radical scavenging ability of bidentate iron (III) chelators. Biochem. Pharmacol. 1998, 55, 1327-1332.
21. D. Kahana N. Kampel V. Warshawsky, A. Youdim, M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 2004, 46, 254-263.
22. Dickens, M.G.; Franz, K.J. A Prochelator activated by hydrogen peroxide prevents metal-induced amyloid beta aggregation. Chem. Bio. Chem. 2010, 11, 59-62.
23. Di Vaira, M.; Bazzicalupi, C.; Orioli, P.; Messori, L.; Bruni, B.; Zatta, P. Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg. Chem. 2004, 43, 3795-3797.
24. Cacciatore, I.; Baldassarre, L.; Fornasari, E.; Mollica, A.; Pinnen, F. Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. Oxid. Med. Cell. Longev. 2012, 240146.
25. Li, L.; Xu, B. Synthesis and characterization of 5-substituted 8-hydroxyquinoline derivatives and their metal complexes. Tetrahedron 2008, 64, 10986-10995.
26. Nefkens, G.H. L.; Tesser, G.I. A novel activated ester in peptide syntheses. J. Am. Chem. Soc. 1961, 83, 1263-1263.
27. Xie, H.; Hu, L.; Li, G. SH-SY5Y human neuroblastoma cells line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin. Med. J. 2010, 123, 1086-1092.
28. Lombet, A.; Zujovic, V.; Kandouz, M.; Billardon, C.; Carvajal-Gonzalez, S.; Gompel, A.; Rostène, W. Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation: Role of Bcl-2 protein family. Eur. J. Biochem. 2001, 268, 1352-1362.
29. Ho, R.; Minturn, J.E.; Hishiki, T.; Zhao, H.; Wang, Q.; Cnaan, A.; Maris, J.; Evans, A.E.; Brodeur, G.M. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 2005, 65, 9868-9875.
30. Jantas, D.; Pytel, M.; Mozrzymas, J.W.; Leskiewicz, M.; Regulska, M.; Antkiewicz-Michaluk, L.; Lason, W. The attenuating effect of memantine on staurosporine-, salsolinol- and doxorubicin- induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem. Int. 2008, 52, 864-877.
31. Middlemas, D.S.; Kihl, B.K.; Moody, N.M. Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents. J. Neuro-Oncol. 1999, 45, 27-36.
32. Tieu, K.; Zuo, D.M.; Yu, P.H. Differential effects of staurosporine and retinoic acid on the vulnerability of the SH-SY5Y neuroblastoma cells: Involvement of Bcl-2 and p53 proteins. J. Neurosci. Res. 1999, 58, 426-435.
33. LeBel, C.P.; Ischiropoulos, H.; Bondy, S.C. Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 1992, 5, 227-231.
34. Lopes, F.M.; Londero, G.F.; de Medeiros, L.M.; da Motta, L.L.; Behr, G.A.; de Oliveira, V.A.; Ibrahim, M.; Moreira, J.C.; de Oliveira Porciúncula, L.; da Rocha, J.B.; Klamt, F. Evaluation of the neurotoxic/neuroprotective role of organoselenides using differentiated human neuroblastoma SH-SY5Y cell line challenged with 6-hydroxydopamine. Neurotox Res., 2012; 22, 138-149.
35. Lopes, F.M.; Schröder, R.; da Frota, M.L.; Zanotto-Filho, A.; Müller, C.B.; Pires, A.S.; Meurer, R.T.; Colpo, G.D.; Gelain, D.P.; Kapczinski, F.; Moreira, J.C.; Fernandes Mda, C.; Klamt, F. Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies. Brain Res. 2010, 1337, 85-94.
36. Lehmensiek, V.; Tan, E.M.; Liebau, S.; Lenk, T.; Zettlmeisl, H.; Schwarz, J.; Storch, A. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant α-synucleins related to Parkinson's disease. Neurochem. Int. 2006, 48, 329-340.
37. Presgraves, S.P.; Ahmed, T.; Borwege, S.; Joyce, J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 2003, 5, 579-598.
38. Cacciatore, I.; Baldassarre, L.; Fornasari, E.; Cornacchia, C.; Di Stefano, A.; Sozio, P.; Cerasa, L.S.; Fontana, A.; Fulle, S.; Di Filippo, E.S.; La Rovere, R.M.; Pinnen, F. (R)-alpha-Lipoyl- glycyl-L-prolyl-L-glutamyl dimethyl ester codrug as multifunctional agent with potential neuroprotective activities. Chem. Med. Chem. 2012, 7, 2021-2029.
39. Menghini, L.; Leporini, L.; Scanu, N.; Pintore, G.; La Rovere, R.; Di Filippo, E.S.; Pietrangelo, T.; Fulle, S. Effect of phytochemicals concentrations on biological activities of cranberry extracts. J. Biol. Reg. Homeos. Ag. 2011, 25, 27-35.